In vivo screening of S100B inhibitors for melanoma therapy.
about
Complex formation between S100B protein and the p90 ribosomal S6 kinase (RSK) in malignant melanoma is calcium-dependent and inhibits extracellular signal-regulated kinase (ERK)-mediated phosphorylation of RSKCovalent small molecule inhibitors of Ca(2+)-bound S100B.S100 proteins in cancer.S100B-p53 disengagement by pentamidine promotes apoptosis and inhibits cellular migration via aquaporin-4 and metalloproteinase-2 inhibition in C6 glioma cells.Upregulation of S100P, receptor for advanced glycation end products and ezrin in malignant melanoma.
P2860
In vivo screening of S100B inhibitors for melanoma therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
In vivo screening of S100B inhibitors for melanoma therapy.
@en
In vivo screening of S100B inhibitors for melanoma therapy.
@nl
type
label
In vivo screening of S100B inhibitors for melanoma therapy.
@en
In vivo screening of S100B inhibitors for melanoma therapy.
@nl
prefLabel
In vivo screening of S100B inhibitors for melanoma therapy.
@en
In vivo screening of S100B inhibitors for melanoma therapy.
@nl
P2093
P2860
P1476
In vivo screening of S100B inhibitors for melanoma therapy.
@en
P2093
Danna B Zimmer
David J Weber
Rena G Lapidus
P2860
P304
P356
10.1007/978-1-62703-230-8_18
P407
P577
2013-01-01T00:00:00Z